Quanta Home Run Trial
Primary Purpose
Renal Failure
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SC+ Hemodialysis System
Sponsored by
About this trial
This is an interventional treatment trial for Renal Failure focused on measuring Hemodialysis
Eligibility Criteria
Inclusion Criteria:
- Provision of a written informed consent form signed by the participant
- Age between 18 and 80 years at time of enrollment
- A care partner must be available for training on SC+ and to be present in the home during all home hemodialysis sessions
- Participants should be either receiving regular, facility-based hemodialysis therapy for at least 90 days, or in the case of peritoneal patients transitioning to hemodialysis, at least 90 days, or performing home dialysis (with any frequency) for at least 90 days and willing to return to facility for purpose of study, and should be clinically stable and deemed suitable for home dialysis in the opinion of the principal investigator
- Willing to accept a dialysis prescription of 3 sessions per week, 4 hours each session or facility standard during in-clinic visits; 4 sessions, 3.5 hours each session during in-home sessions
- In the opinion of the Investigator, participant has well-functioning and stable vascular access (tunneled, central venous catheter, arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min
- Home environment is adequate to ensure that appropriate electrical connections and water supply necessary for the use and storage of the device as assessed by Quanta prior to subject C1 visit. Also ensure that cellular signal and/or WIFI capacity is adequate.
- Participant or care partner are capable of understanding the nature of procedures and requirements of the study protocol and of home-based hemodialysis, and are willing and capable of complying with protocol and returning to treatment center as stated in protocol
- Participant or care partner are capable of being trained to use the machine and troubleshoot should an alarm situation occur
- In the opinion of the treating physician, the subject is able to participate in the trial in terms of social factors and personal functioning
- Acceptable physical ability of the participant and/or care partner to perform the hemodialysis treatment at home
- Financial coverage for treatment costs by Medicare, Medicaid, private insurance, or other arrangement acceptable to participant
Exclusion Criteria:
- Pregnant or trying to become pregnant (women of childbearing potential must use medically accepted contraceptive measures)
- Predicted life expectancy of less than 12 months from first study procedure
- Major cardiovascular adverse event in the 3 months prior to screening
- Fluid overload due to intractable ascites secondary to liver cirrhosis
- Uncontrolled or unstable blood pressure (systolic BP outside the range 90 to 180 mmHg)
- Unstable coronary artery disease
- New York Class III or IV heart failure, or ejection fraction less than 30%
- Participation in other clinical studies that may interfere with the current protocol
- Known problems with coagulation
- Active, life-threatening, rheumatologic disease.
- Hematocrit less than 28% at enrollment
- Hemoglobin less than 9 g/dL at enrollment
- Suffering from active severe infection
- Seroreactive for hepatitis B surface antigen
- Suffering from active malignancy with expected deteriorating course within 6-12 months
- History of severe reactions to dialyzer membrane material
- Expected to receive an organ transplant during the course of the study
- Have dementia or inability to understand procedures
- Lack an ability for self-care
- Are non-adherent to their current dialysis treatments
- Experience intra-dialytic hypotension defined as a decrease in systolic blood pressure of greater than or equal to 20 mmHg or a decrease in mean arterial pressure of greater than or equal to 10 mmHg provided that the decrease is associated with clinical events (symptoms) and the need for an intervention (ultrafiltration turned off, bolus of fluid) in 3 of 5 previous treatments
- Is intolerant to heparin
- Considered in the investigator's opinion to be clinically unstable for any other reason
- Undergoing outpatient dialysis for the treatment of acute kidney injury (AKI)
Sites / Locations
- Capital Nephrology Medical Group
- Home Dialysis Therapies of San Diego / UCSD
- Satellite WellBound
- Satellite - WellBound
- Satellite - WellBound
- High Desert Nephrology Medical Group
- Ocala RKCHD At Home
- Southeastern Clinical Research Institute, LLC
- DaVita Home Dialysis of Indianapolis
- New Hyde Park Dialysis Center
- Hypertension & Kidney Specialists
- aQua Research Institute, LLC
- Northwest Kidney Centers
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Hemodialysis Treatments
Arm Description
All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
Outcomes
Primary Outcome Measures
Mean Standardized Weekly Kt/V (Efficacy)
Mean standardized weekly Kt/V greater than or equal to 2.1, using a hemodialysis prescription of 4 sessions per week for 3.5 hours per session, measured for dialysis delivered during the home portion of the study.
Adverse Event Rate
Adverse event rate: the number of adverse events per 100 treatments that occurred during the study, as defined by:
Serious adverse event (SAE)
Allergic reaction: type A, anaphylactoid or type B dialyzer reactions to dialyzer, blood tubing, or chemical disinfectant.
Blood loss: resulting in hemodynamic compromise that led to death, transfusion, or fluid resuscitation with greater than 1 liter of crystalloid IV fluids.
Hemolytic reaction: due to disinfectant exposure, dialysate temperature, mechanical failure, or other device related causes.
Infection: related to hemodialysis catheter, its tunnel or exit site, arteriovenous fistula (AVF), or arteriovenous graft (AVG).
Intradialytic event: a significant clinical event such as loss of consciousness, cardiac arrest, or seizure caused by device failure.
Vascular access complication
Pyrogenic reaction
Intradialytic hypotension
Secondary Outcome Measures
Number of SAEs and device-related SAEs
Number of SAEs per 100 treatments occurring in the in-clinic portion of the study compared with those occurring in the home portion
Number of device-related SAEs per 100 treatments in the in-clinic portion of the study compared with those occurring in the home portion
Number of adverse events per 100 treatments occurring in the in-clinic portion of the study compared with those occurring in the home portion
Additional adverse events of special interest:
Air in blood tubing that cannot be resolved through usual procedure
30 minutes post dialysis elevated systolic blood pressure > 180 mmHg or low systolic blood pressure < 90 mmHg on two consistent treatments
Significantly elevated (<100 mmHg or > 250 mmHg) arterial or venous pressures in 3 consecutive sessions
Specific hematology laboratory values will be collected and compared to target ranges from clinical practice guidelines.
Full Information
NCT ID
NCT04975880
First Posted
July 14, 2021
Last Updated
July 25, 2023
Sponsor
Quanta Dialysis Technologies Ltd
1. Study Identification
Unique Protocol Identification Number
NCT04975880
Brief Title
Quanta Home Run Trial
Official Title
A Prospective, Multi-Center, Open-Label Assessment of Efficacy and Safety of Quanta SC+ for Home Hemodialysis
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 18, 2021 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
February 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Quanta Dialysis Technologies Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine non-inferiority in safety and efficacy when Quanta SC+ is used in the self-care home environment compared to a hemodialysis facility.
Detailed Description
This clinical trial is being conducted to evaluate the Quanta SC+ hemodialysis System for home use by patients with established kidney failure. A dialysis prescription of 3 sessions per week, 4 hours per session, or facility standard will be provided during the in-clinic training period, followed by the home period with a dialysis prescription of 4 sessions per week, 3.5 hours per session.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Failure
Keywords
Hemodialysis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Following enrollment participants will begin hemodialysis treatments on the SC+ machine on a prescription of four-hour treatments, three times per week or per facility standard for training within a hemodialysis facility for a minimum of 4 weeks.
During this time, both patients and caregivers will undergo extensive training and competency sign off on all aspects of safely administering hemodialysis treatment in the home. This 4 week period can be extended week by week to a maximum of 8 weeks until competency sign off is achieved.
Upon completion of training, a 1 week transition period will occur followed by the home hemodialysis phase (test phase) which consists of 8 weeks of treatments performed 4 times per week, 3.5 hours each treatment in the participant's home setting by the participant or their care partner.
Masking
None (Open Label)
Allocation
N/A
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hemodialysis Treatments
Arm Type
Other
Arm Description
All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
Intervention Type
Device
Intervention Name(s)
SC+ Hemodialysis System
Intervention Description
Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
Primary Outcome Measure Information:
Title
Mean Standardized Weekly Kt/V (Efficacy)
Description
Mean standardized weekly Kt/V greater than or equal to 2.1, using a hemodialysis prescription of 4 sessions per week for 3.5 hours per session, measured for dialysis delivered during the home portion of the study.
Time Frame
8 weeks per period
Title
Adverse Event Rate
Description
Adverse event rate: the number of adverse events per 100 treatments that occurred during the study, as defined by:
Serious adverse event (SAE)
Allergic reaction: type A, anaphylactoid or type B dialyzer reactions to dialyzer, blood tubing, or chemical disinfectant.
Blood loss: resulting in hemodynamic compromise that led to death, transfusion, or fluid resuscitation with greater than 1 liter of crystalloid IV fluids.
Hemolytic reaction: due to disinfectant exposure, dialysate temperature, mechanical failure, or other device related causes.
Infection: related to hemodialysis catheter, its tunnel or exit site, arteriovenous fistula (AVF), or arteriovenous graft (AVG).
Intradialytic event: a significant clinical event such as loss of consciousness, cardiac arrest, or seizure caused by device failure.
Vascular access complication
Pyrogenic reaction
Intradialytic hypotension
Time Frame
8 weeks per period
Secondary Outcome Measure Information:
Title
Number of SAEs and device-related SAEs
Description
Number of SAEs per 100 treatments occurring in the in-clinic portion of the study compared with those occurring in the home portion
Number of device-related SAEs per 100 treatments in the in-clinic portion of the study compared with those occurring in the home portion
Number of adverse events per 100 treatments occurring in the in-clinic portion of the study compared with those occurring in the home portion
Additional adverse events of special interest:
Air in blood tubing that cannot be resolved through usual procedure
30 minutes post dialysis elevated systolic blood pressure > 180 mmHg or low systolic blood pressure < 90 mmHg on two consistent treatments
Significantly elevated (<100 mmHg or > 250 mmHg) arterial or venous pressures in 3 consecutive sessions
Specific hematology laboratory values will be collected and compared to target ranges from clinical practice guidelines.
Time Frame
8 weeks per period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provision of a written informed consent form signed by the participant
Age between 18 and 80 years at time of enrollment
A care partner must be available for training on SC+ and to be present in the home during all home hemodialysis sessions
Participants should be either receiving regular, facility-based hemodialysis therapy for at least 90 days, or in the case of peritoneal patients transitioning to hemodialysis, at least 90 days, or performing home dialysis (with any frequency) for at least 90 days and willing to return to facility for purpose of study, and should be clinically stable and deemed suitable for home dialysis in the opinion of the principal investigator
Willing to accept a dialysis prescription of 3 sessions per week, 4 hours each session or facility standard during in-clinic visits; 4 sessions, 3.5 hours each session during in-home sessions
In the opinion of the Investigator, participant has well-functioning and stable vascular access (tunneled, central venous catheter, arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min
Home environment is adequate to ensure that appropriate electrical connections and water supply necessary for the use and storage of the device as assessed by Quanta prior to subject C1 visit. Also ensure that cellular signal and/or WIFI capacity is adequate.
Participant or care partner are capable of understanding the nature of procedures and requirements of the study protocol and of home-based hemodialysis, and are willing and capable of complying with protocol and returning to treatment center as stated in protocol
Participant or care partner are capable of being trained to use the machine and troubleshoot should an alarm situation occur
In the opinion of the treating physician, the subject is able to participate in the trial in terms of social factors and personal functioning
Acceptable physical ability of the participant and/or care partner to perform the hemodialysis treatment at home
Financial coverage for treatment costs by Medicare, Medicaid, private insurance, or other arrangement acceptable to participant
Exclusion Criteria:
Pregnant or trying to become pregnant (women of childbearing potential must use medically accepted contraceptive measures)
Predicted life expectancy of less than 12 months from first study procedure
Major cardiovascular adverse event in the 3 months prior to screening
Fluid overload due to intractable ascites secondary to liver cirrhosis
Uncontrolled or unstable blood pressure (systolic BP outside the range 90 to 180 mmHg)
Unstable coronary artery disease
New York Class III or IV heart failure, or ejection fraction less than 30%
Participation in other clinical studies that may interfere with the current protocol
Known problems with coagulation
Active, life-threatening, rheumatologic disease.
Hematocrit less than 28% at enrollment
Hemoglobin less than 9 g/dL at enrollment
Suffering from active severe infection
Seroreactive for hepatitis B surface antigen
Suffering from active malignancy with expected deteriorating course within 6-12 months
History of severe reactions to dialyzer membrane material
Expected to receive an organ transplant during the course of the study
Have dementia or inability to understand procedures
Lack an ability for self-care
Are non-adherent to their current dialysis treatments
Experience intra-dialytic hypotension defined as a decrease in systolic blood pressure of greater than or equal to 20 mmHg or a decrease in mean arterial pressure of greater than or equal to 10 mmHg provided that the decrease is associated with clinical events (symptoms) and the need for an intervention (ultrafiltration turned off, bolus of fluid) in 3 of 5 previous treatments
Is intolerant to heparin
Considered in the investigator's opinion to be clinically unstable for any other reason
Undergoing outpatient dialysis for the treatment of acute kidney injury (AKI)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Komenda, MD
Organizational Affiliation
Quanta Dialysis Technology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Christopher T Chan, MD
Organizational Affiliation
University of Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
Capital Nephrology Medical Group
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Home Dialysis Therapies of San Diego / UCSD
City
San Diego
State/Province
California
ZIP/Postal Code
92131
Country
United States
Facility Name
Satellite WellBound
City
San Leandro
State/Province
California
ZIP/Postal Code
94577
Country
United States
Facility Name
Satellite - WellBound
City
San Mateo
State/Province
California
ZIP/Postal Code
94403
Country
United States
Facility Name
Satellite - WellBound
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95407
Country
United States
Facility Name
High Desert Nephrology Medical Group
City
Victorville
State/Province
California
ZIP/Postal Code
92392
Country
United States
Facility Name
Ocala RKCHD At Home
City
Ocala
State/Province
Florida
ZIP/Postal Code
32724
Country
United States
Facility Name
Southeastern Clinical Research Institute, LLC
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30904
Country
United States
Facility Name
DaVita Home Dialysis of Indianapolis
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Facility Name
New Hyde Park Dialysis Center
City
New Hyde Park
State/Province
New York
ZIP/Postal Code
11040
Country
United States
Facility Name
Hypertension & Kidney Specialists
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17604
Country
United States
Facility Name
aQua Research Institute, LLC
City
Houston
State/Province
Texas
ZIP/Postal Code
77058
Country
United States
Facility Name
Northwest Kidney Centers
City
Seattle
State/Province
Washington
ZIP/Postal Code
98122
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Quanta Home Run Trial
We'll reach out to this number within 24 hrs